Nanjing IASO Biotechnology Co., Ltd.
Works in Cardiovascular · Dermatology · Hematology · Immunology · Metabolic & endocrine · Oncology · Renal & urogenital · Women's health
Nanjing IASO Biotechnology Co., Ltd. is a clinical trial sponsor. It has 10 active clinical trials with 2,069 planned participants, across 8 therapeutic areas.
Trial track record · since 2021
Pipeline · 10 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Nanjing IASO Biotechnology Co., Ltd
Nanjing IASO Biotechnology Co., Ltd is lead sponsor of 10 active clinical trials on ClinicalTrials.gov, with 2,069 planned participants, in Cardiovascular, Dermatology, Hematology, Immunology and other areas. Since 2021 it has completed 0 trials and stopped 0 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Nanjing IASO Biotechnology Co., Ltd; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-11-06.
Approve Suite is not affiliated with Nanjing IASO Biotechnology Co., Ltd..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.